Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1488 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Greg Rigdon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sirtsei Pharmaceuticals, Inc., a Subsidiary of Arrivo BioVentures, Morrisville, NC, USA. Hauptthemen laut MEDLINE: Food-Drug Interactions, Healthy Volunteers, Sirtuins, Benzofurans. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Sirtuin 6 activation is a novel epigenetic mechanism proposed for treatment of depression. Two Phase 1 studies, SP‐624‐101 and SP‐624‐102, examined the pharmacokinetics and safety of SP‐624, an orally active sirtuin 6 activator, in healthy adults. SP‐624‐101 was a single‐ascending‐dose study. In Part A, participants were randomized 6:2 to SP‐624 (single oral doses of 3, 10, or 30 mg) or placebo. Part B compared results in 8 participants receiving SP‐624 while fasting or after a high‐fat, high‐calorie breakfast. In SP‐624‐102, a multiple‐ascending‐dose study, participants were randomized 6:2 to SP‐624 (3 or 10 mg SP‐624 daily) or placebo for 5 days and 5:2 to SP‐624 20 mg daily or placebo for 10 days. At all doses, maximum concentration (C max ) exceeded predicted target plasma concentrations of 3.28 ng/mL. Area under the concentration‐time curve and C max increased dose proportionally. A food effect resulted in significantly lower C max , later time to maximum concentration , and comparable AUC for fed versus fasting participants. No serious adverse events were observed. In SP‐624‐101 and SP‐624‐102, respectively, 3 (12%) and 5 (29%) SP‐624–treated participants experienced treatment‐emergent adverse events. SP‐624 was well tolerated and reached target concentrations in healthy adults, supporting progression of SP‐624 20 mg daily into Phase 2 studies of major depressive disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sirtsei Pharmaceuticals, Inc., a Subsidiary of Arrivo BioVentures, Morrisville, NC, USA.
Zitieren
APA
Rigdon, G., Prescott, Y., Hall, J., Abernathy, K., Raskin, J., & Wargin, W. (2025). Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1488
Vancouver
Rigdon G, Prescott Y, Hall J, Abernathy K, Raskin J, Wargin W. Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1488
BibTeX
@article{Rigdon2025,
author = {Rigdon, Greg and Prescott, Yuki and Hall, John and Abernathy, Kelly and Raskin, Joel and Wargin, William},
title = {Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1488}
}
EUVIMED